WO2018174585A3 - 뇌의 베타 아밀로이드 축적 감별용 혈중 바이오마커 - Google Patents

뇌의 베타 아밀로이드 축적 감별용 혈중 바이오마커 Download PDF

Info

Publication number
WO2018174585A3
WO2018174585A3 PCT/KR2018/003340 KR2018003340W WO2018174585A3 WO 2018174585 A3 WO2018174585 A3 WO 2018174585A3 KR 2018003340 W KR2018003340 W KR 2018003340W WO 2018174585 A3 WO2018174585 A3 WO 2018174585A3
Authority
WO
WIPO (PCT)
Prior art keywords
discerning
brain
blood biomarker
beta amyloid
amyloid accumulation
Prior art date
Application number
PCT/KR2018/003340
Other languages
English (en)
French (fr)
Other versions
WO2018174585A2 (ko
Inventor
묵인희
한선호
박종찬
Original Assignee
서울대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서울대학교산학협력단 filed Critical 서울대학교산학협력단
Priority to EP18770858.1A priority Critical patent/EP3608424A4/en
Priority to JP2019552049A priority patent/JP6970983B2/ja
Priority to US16/496,547 priority patent/US11193946B2/en
Publication of WO2018174585A2 publication Critical patent/WO2018174585A2/ko
Publication of WO2018174585A3 publication Critical patent/WO2018174585A3/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01007—Acetylcholinesterase (3.1.1.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/15—Peptidyl-dipeptidases (3.4.15)
    • C12Y304/15001—Peptidyl-dipeptidase A (3.4.15.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

본원은 알츠하이머성 치매 원인물질인 아밀로이드 베타의 뇌 침착에 대한 혈액 바이오마커에 관한 것이다. 본원에 따른 마커는 혈액을 이용하여 간편하고 신속하게 뇌 아밀로이드 베타 축적을 예측할 수 있어, 임상이 나타나기 전의 경도 인지장애 등을 포함하는 이와 관련된 질환의 진단 등에 효과적으로 사용될 수 있다.
PCT/KR2018/003340 2017-03-23 2018-03-22 뇌의 베타 아밀로이드 축적 감별용 혈중 바이오마커 WO2018174585A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP18770858.1A EP3608424A4 (en) 2017-03-23 2018-03-22 BIOMARKERS TO TREAT BETA AMYLOID BUILD UP IN THE BRAIN
JP2019552049A JP6970983B2 (ja) 2017-03-23 2018-03-22 脳のアミロイドベータ蓄積鑑別用血中バイオマーカー
US16/496,547 US11193946B2 (en) 2017-03-23 2018-03-22 Blood biomarker for discerning beta amyloid accumulation in brain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0036625 2017-03-23
KR20170036625 2017-03-23

Publications (2)

Publication Number Publication Date
WO2018174585A2 WO2018174585A2 (ko) 2018-09-27
WO2018174585A3 true WO2018174585A3 (ko) 2019-01-10

Family

ID=63585571

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/003340 WO2018174585A2 (ko) 2017-03-23 2018-03-22 뇌의 베타 아밀로이드 축적 감별용 혈중 바이오마커

Country Status (5)

Country Link
US (1) US11193946B2 (ko)
EP (1) EP3608424A4 (ko)
JP (3) JP6970983B2 (ko)
KR (3) KR102064060B1 (ko)
WO (1) WO2018174585A2 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102254053B1 (ko) * 2018-10-25 2021-05-20 서울대학교산학협력단 인지기능 정상군 또는 경도 인지장애에서 아밀로이드 베타의 뇌 침착 검출용 혈액 바이오 마커
KR20200051398A (ko) 2018-11-05 2020-05-13 인하대학교 산학협력단 치매 진단을 위한 비강 분비물 내 단백질 분석 장치 및 방법
KR102561438B1 (ko) 2020-11-04 2023-07-28 사회복지법인 삼성생명공익재단 뇌 아밀로이드 베타 축적 가능성을 예측하는 방법
WO2023068173A1 (ja) * 2021-10-18 2023-04-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 脳内アミロイドβの蓄積を評価するためのバイオマーカー
WO2024005008A1 (ja) * 2022-06-28 2024-01-04 大塚製薬株式会社 シヌクレイノパチーを判定するための方法
CN114999656B (zh) * 2022-07-27 2023-01-03 苏州药明泽康生物科技有限公司 一种阿尔兹海默病风险评估系统及模块

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140042331A (ko) * 2012-09-28 2014-04-07 서울대학교산학협력단 인지장애 질환 진단용 다중 마커 및 그 용도
KR20160129444A (ko) * 2015-04-30 2016-11-09 서울대학교산학협력단 혈장 내 아밀로이드베타의 농도를 통해 알츠하이머병을 임상학적 및 병리학적으로 모니터링하는 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US481656A (en) 1892-08-30 Cutter or drill
JP3265577B2 (ja) * 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法
US6136548A (en) * 1994-11-22 2000-10-24 Rutgers, The State University Of New Jersey Methods for identifying useful T-PA mutant derivatives for treatment of vascular hemorrhaging
US20030119074A1 (en) * 2001-12-20 2003-06-26 George Jackowski Diagnosis and treatment of dementia utilizing thrombospondin
WO2008091948A2 (en) 2007-01-23 2008-07-31 University Of Virginia Patent Foundation Galectin-3-binding, protein as a biomarker of cardiovascular disease
WO2009138392A1 (en) 2008-05-14 2009-11-19 ETH Zürich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
KR20100049363A (ko) 2008-11-03 2010-05-12 서울대학교산학협력단 비타민 ｄ 결합 단백질을 이용한 알츠하이머병의 진단장치 및 진단방법
JP2011237402A (ja) 2010-04-14 2011-11-24 Mitsubishi Chemicals Corp ガレクチン−３結合蛋白質による脳梗塞の検査方法
KR101240207B1 (ko) 2010-08-27 2013-03-06 고려대학교 산학협력단 알츠하이머병 조기진단용 단백질성 마커
WO2012149607A1 (en) * 2011-05-03 2012-11-08 Commonwealth Scientific And Industrial Research Organisation Method for detection of a neurological disease
EP3039431A4 (en) * 2013-08-27 2017-05-03 CRC for Mental Health Ltd. Method of identifying biomarkers of neurological diseases and diagnosis of neurological diseases
AU2015262399B9 (en) * 2014-05-22 2021-07-22 National Center For Geriatrics And Gerontology Surrogate biomarker for evaluating intracerebral amyloid beta peptide accumulation and method for analysis thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140042331A (ko) * 2012-09-28 2014-04-07 서울대학교산학협력단 인지장애 질환 진단용 다중 마커 및 그 용도
KR20160129444A (ko) * 2015-04-30 2016-11-09 서울대학교산학협력단 혈장 내 아밀로이드베타의 농도를 통해 알츠하이머병을 임상학적 및 병리학적으로 모니터링하는 방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAIRD, ALISON L. ET AL.: "Blood-based Proteomic Biomarkers of Alzheimer's Disease Pathology", FRONTIERS IN NEUROLOGY, vol. 6, no. 236, 2015, pages 1 - 16, XP055465994 *
FRANCOIS, MAXIME ET AL.: "High Content, Multi-parameter Analyses in Buccal Cells to identify Alzheimer's Disease", CURRENT ALZHEIMER RESEARCH, vol. 13, no. 7, 2016, pages 787 - 799, XP055561118 *
RASMUSSEN, KATRINE L. ET AL.: "Plasma Levels of Apolipoprotein E and Risk of Dementia in the General Population", ANNALS OF NEUROLOGY, vol. 77, 2015, pages 301 - 311, XP055561123 *

Also Published As

Publication number Publication date
US20210215719A1 (en) 2021-07-15
JP7105510B2 (ja) 2022-07-25
JP2021181999A (ja) 2021-11-25
KR102064060B1 (ko) 2020-02-11
US11193946B2 (en) 2021-12-07
JP7105510B6 (ja) 2022-08-15
JP6970983B2 (ja) 2021-11-24
KR20180108469A (ko) 2018-10-04
KR102130929B1 (ko) 2020-07-06
JP2021182000A (ja) 2021-11-25
KR20190139827A (ko) 2019-12-18
JP2020511662A (ja) 2020-04-16
KR102067944B1 (ko) 2020-02-11
KR20190139826A (ko) 2019-12-18
EP3608424A4 (en) 2020-12-09
EP3608424A2 (en) 2020-02-12
WO2018174585A2 (ko) 2018-09-27

Similar Documents

Publication Publication Date Title
WO2018174585A3 (ko) 뇌의 베타 아밀로이드 축적 감별용 혈중 바이오마커
ECSP19075146A (es) ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
EP3299473A4 (en) Method for diagnosing early onset of alzheimer's disease or mild cognitive impairment
PH12020500573A1 (en) 1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indole derivatives for the treatment, alleviation or prevention of disorders associated with tau aggregates like alzheimer`s disease
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
AU2015286707A8 (en) Improved A beta protofibril binding antibodies
SG11202011018PA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
EP3577455A4 (en) BIOMARKERS FOR THE DIAGNOSIS AND CHARACTERIZATION OF ALZHEIMER'S DISEASE
EP3405215A4 (en) METHOD FOR THE TREATMENT OF MORBUS DANON AND OTHER AUTOPHAGIC DISEASES
EA201791993A1 (ru) Способы лечения протеинопатий
SG11202011010YA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
NI202000005A (es) Agentes, usos y métodos para el tratamiento
WO2017066796A3 (en) Modulators of telomere disease
MY186560A (en) Protein purification
KR102354980B9 (ko) 전안부 질환 진단 시스템 및 이를 이용한 진단 방법
EP3806957A4 (en) METHODS FOR DIAGNOSING, MONITORING AND TREATING NEUROLOGICAL DISEASES AND DISORDERS
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
GB2557471A (en) Arginine silicate inositol for improving cognitive function
EA201990450A1 (ru) Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания
WO2015166045A3 (en) Alkaline phosphatase for use in the treatment of neurodegenerative and neuronal diseases
EP4072587A4 (en) DEBARYOMYCES SPECIES AS AN INDICATOR OF NON-HEALING ULCERS IN CROHN’S DISEASE
EP3861352A4 (en) NOVEL BIOMARKER FOR HUMAN ALZHEIMER'S DISEASE
RU2013110326A (ru) Способ диагностики нейродегенеративных заболеваний
EP3551051A4 (en) METHODS FOR DIAGNOSING ALZHEIMER'S DISEASE AND THE RISK OF DEVELOPING ALZHEIMER'S DISEASE
WO2021041573A3 (en) Biomarkers for neurodegenerative disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18770858

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2019552049

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018770858

Country of ref document: EP

Effective date: 20191023